GSK bolsters vaccines division with $3.3bn swoop on Affinivax
GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax, with another $1.2 billion in potential development milestones, to …
GSK bolsters vaccines division with $3.3bn swoop on Affinivax Read More »